2018-05-11T16:16:00-05:00 2017-06-30 ERNST & YOUNG US LLP 4365 EXECUTIVE DRIVE STE 1600 SAN DIEGO CA 92121 990 2016-07-01 510197108 SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE % GARY CHESSUM SANF 8586463100 10901 North Torrey Pines Road La Jolla CA 92037 GARY CHESSUM CFO 8586463100 2018-05-11 true DEBRA HEISKALA P00649485 8585357200 2016 2022-09-23 18:48:47Z Kristiina Vuori 10901 North Torrey Pines Road La Jolla CA 92037 340385736 false X www.sbpdiscovery.org X 1976 CA SEE SCHEDULE O 22 20 983 25 2133255 281883 112687922 121777889 1984033 1413894 9787422 5628894 4645694 5353488 129105071 134174165 0 0 0 0 77528317 79341143 0 0 1574342 64840277 67504171 142368594 146845314 -13263523 -12671149 517058113 482051570 207862462 174862590 309195651 307188980 X SEE SCHEDULE O false false 119849856 0 1700572 SEE SCHEDULE O 119849856 true true false true false false false false false true true false false false false true true false false true true false false false true false false false false true true false false false false false true false false false false false false false false false true true false false false true 229 0 true 983 true true true false false false false true true false false false false X 22 20 false false false false false false false true true false false true true true true true true true true false AL AK AR CA CO CT DC FL GA IL KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X GARY CHESSUM 8586463100 10901 N TORREY PINES RD LA JOLLA CA 92037 PERRY NISEN MD PHD CEO 50.0 0.0 X X 1115133 0 122179 DOUGLAS OBENSHAIN TRUSTEE 1.0 0.0 X 0 0 0 BERNARD MACHEN TRUSTEE (PART YEAR) 1.0 0.0 X 0 0 0 DAVID DOWN TRUSTEE 1.0 0.0 X 0 0 0 WILLIAM GERHART TRUSTEE 1.0 0.0 X 0 0 0 RASESH THAKKAR TRUSTEE (PART YEAR) 1.0 0.0 X 0 0 0 LUDER WHITLOCK TRUSTEE 1.0 0.0 X 0 0 0 LORENZO BERHO TRUSTEE 1.0 0.0 X 0 0 0 DANIEL EPSTEIN TRUSTEE 1.0 0.0 X 0 0 0 WAINWRIGHT FISHBURN TRUSTEE 1.0 0.0 X 0 0 0 PATRICK GERAGHTY TRUSTEE (PART YEAR) 1.0 0.0 X 0 0 0 ALAN GLEICHER TRUSTEE 1.0 0.0 X 0 0 0 JEANNE HERBERGER TRUSTEE 1.0 0.0 X 0 0 0 DONALD JERNIGAN TRUSTEE 1.0 0.0 X 0 0 0 DOUG MANCHESTER TRUSTEE (PART YEAR) 1.0 0.0 X 0 0 0 EDWARD SCHULAK TRUSTEE 1.0 0.0 X 0 0 0 STUART TANZ TRUSTEE 1.0 0.0 X 0 0 0 CAROL GALLAGHER TRUSTEE 1.0 0.0 X 0 0 0 GREG LUCIER TRUSTEE 1.0 0.0 X 0 0 0 JAMES JARDON TRUSTEE 1.0 0.0 X 0 0 0 DONALD ROSENBERG TRUSTEE 1.0 0.0 X 0 0 0 JAMES MYERS TRUSTEE 1.0 0.0 X 0 0 0 KAZUMI SHIOSAKI TRUSTEE 1.0 0.0 X 0 0 0 HENRY NORDOFF CHAIRMAN 1.0 0.0 X X 0 0 0 JAMES BLAIR VICE CHAIR 1.0 0.0 X X 0 0 0 KRISTIINA VUORI MD PHD PRESIDENT 50.0 0.0 X X 886682 0 565924 PAULINE FOSTER TRUSTEE (PART YEAR) 1.0 0.0 X 0 0 0 KNOX BELL CORPORATE SECRETARY 2.0 0.0 X 0 0 0 GARY CHESSUM CFO 50.0 0.0 X 418910 0 36262 GARTH POWIS PHD CENTER DIRECTOR 50.0 0.0 X 503978 0 42359 DANIEL KELLY MD CNTR DIR/SCI DIR AT LK NONA 50.0 0.0 X 502023 0 50731 EDWARD LEWANDOWSKI PROFESSOR 50.0 0.0 X 518581 0 23914 CARL WARE PHD CENTER DIRECTOR, IIDC 50.0 0.0 X 417535 0 42616 MICHAEL JACKSON PHD DRUG DISCOVERY & DEV, SR VP 50.0 0.0 X 433071 0 50455 GARY RAISL ED D FORMER EVP/CAO/CFP/TREASURER 0.0 0.0 X 365372 0 0 5161285 0 934440 142 true true false DLA PIPER US LLP PO Box 64029 Baltimore MD 21264 Legal SERVICES 634757 Deloitte Touche LLP PO BOX 844708 DALLAS TX 75284 Audit SERVICES 191957 Pabst Patent Group LLP 1545 Peachtree Stree NE Ste 320 Atlanta GA 30309 Legal SERVICES 140269 Kenneth Widder PO BOX 676250 RANCHO SANTA FE CA 92067 Consulting SERVICES 118350 Wilson Sonsini Goodrich PO BOX 742866 Los Angeles CA 90074 Legal SERVICES 111891 5 711165 74902971 46163753 0 121777889 SHARED SERVICES REVENUE 541990 1413894 1413894 0 0 1413894 3146953 3890 3143063 0 3138128 3138128 22560 22560 0 22560 22560 208413269 205931328 2481941 2481941 2481941 57000 711165 280243 -223243 -223243 0 0 0 0 0 0 Research 541700 2129365 0 2129365 0 OTHER RESEARCH SUPPORT 541990 153475 153475 0 0 Sale of Reagents 541990 59006 59006 0 0 74197 74197 0 2416043 134174165 1700572 2133255 8562449 0 0 0 0 0 0 0 0 2391383 243210 2148173 0 0 0 0 60650213 48931572 10917314 801327 3977082 3252754 675228 49100 8692549 7145436 1442886 104227 3629916 2821696 751430 56790 1755607 940071 743178 72358 1069842 52701 1017141 0 400371 0 400371 0 67275 0 67275 0 0 0 15100 0 15100 0 1508777 710539 783576 14662 56734 3155 7777 45802 8813036 7869629 845653 97754 1401290 1102617 263472 35201 0 0 0 0 13450575 12058762 1307241 84572 554902 457532 93631 3739 0 0 0 0 1193091 877587 284224 31280 2162878 1961514 183412 17952 0 0 0 0 13127059 11843510 1225692 57857 146793 146793 0 RESEARCH SUPPLIES & SERV. 14706631 14706631 0 0 Scientific collaborations 4567950 4567950 0 0 Recruitment 250018 189837 60065 116 Bad Debt 1891263 0 1891263 0 364979 113153 150221 101605 146845314 119849856 25421116 1574342 0 4123683 4468804 23499833 21504849 60764502 36509300 1160298 854298 1184978 1137581 0 0 1596813 1160303 214481 177124 6963036 6858015 306494829 171993087 139163665 134501742 263938102 256843206 11800000 15556694 0 0 0 0 2648722 2479654 517058113 482051570 18662124 16961878 0 0 124792172 96699380 64408166 61201332 0 0 0 0 0 0 0 0 0 0 207862462 174862590 X 138987303 180035528 156181232 113099936 14027116 14053516 309195651 307188980 517058113 482051570 -12671149 10664478 0 0 X false true X true true true X 146497371 146698221 244026040 112703072 121777889 771702593 0 0 146497371 146698221 244026040 112703072 121777889 771702593 83084132 688618461 4000400 4044153 6992391 5532193 6303751 26872888 144833 195599 160548 52137 281883 835000 0 799410481 8984298 0.86141 0.85459 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false 0 false 0 false 0 false 0 true 87006 false 0 true 62775 149781 false SCHEDULE C, PART II-B, LINE 1G LOBBYING ACTIVITIES CONTACT AND MEET WITH FEDERAL AND STATE LEGISLATORS AND THEIR STAFF TO SEEK POTENTIAL RESEARCH FUNDING. SCHEDULE C, PART II-B, LINE 1I OTHER ACTIVITIES DUES TO RESEARCH AND BIOMEDICAL ORGANIZATIONS, A PORTION OF WHICH ARE CONSIDERED LOBBYING. THE INSTITUTE UTILIZES ATLANTIC STRATEGIES GROUP, LLC FOR REPRESENTATION IN WASHINGTON DC, TO INVESTIGATE AND SEEK POTENTIAL FEDERAL RESEARCH FUNDING OPPORTUNITIES OUTSIDE THE TRADITIONAL NIH PROCESS. THE INSTITUTE CONTRACTS WITH CAPITAL INSIGHT AND ASSOCIATES FOR REPRESENTATION IN TALLAHASSEE, FL, TO INVESTIGATE AND SEEK POTENTIAL STATE RESEARCH FUNDING OPPORTUNITIES. 25987641 530336 3395420 1232083 28681314 26693919 510067 -3125 1213220 25987641 26870514 920000 36749 1133344 26693919 22805011 1310000 3778222 1022719 26870514 21200471 9000 2517312 921772 22805011 0.46130 0.47220 0.06650 false false 25793087 25793087 166575980 79374694 87201286 113578127 92618393 20959734 547635 547635 134501742 0 0 X 144824000 10664478 457 10664935 134159065 15100 0 15100 134174165 146830000 0 0 146830000 15100 214 15314 146845314 SCHEDULE D, PART V, LINE 4 INTENDED USES OF THE ORGANIZATION'S ENDOWMENT FUNDS THE INSTITUTE'S ENDOWMENT FUNDS ARE ESTABLISHED FOR VARIOUS PURPOSES: SCIENTIFIC RESEARCH, CEO CHAIR, PRESIDENTIAL CHAIR, CANCER AND NEUROSCIENCE LEADERSHIP CHAIRS, AND UNRESTRICTED AS TO INCOME. SCHEDULE D, PART X, LINE 2 FIN 48 (ASC 740) FOOTNOTE THE INSTITUTE HAS NO MATERIAL DEFERRED TAX ASSETS OR DEFERRED TAX LIABILITIES RECORDED AS OF JUNE 30, 2017 AND 2016. THE INSTITUTE DID NOT RECOGNIZE A CHANGE IN LIABILITY FOR UNRECOGNIZED TAX BENEFITS (THE DIFFERENCE BETWEEN A TAX POSITION TAKEN, OR EXPECTED TO BE TAKEN, IN A TAX RETURN AND THE BENEFIT RECOGNIZED AND MEASURED IN THE FINANCIAL STATEMENTS). THERE WERE NO LIABILITIES FOR UNRECOGNIZED TAX BENEFITS AT JUNE 30, 2017 AND 2016. SCHEDULE D, PART XI, LINE 2D ROUNDING - 457 SCHEDULE D, PART XII, LINE 4B ROUNDING - 214 Europe (Including Iceland and Greenland) 49 Program Services See Part V 107967 East Asia and the Pacific 15 Program Services See Part V 39000 North America 4 Program Services See Part V 2311 South Asia 2 Program Services See Part V 9006 Middle East and North Africa 4 Program Services See Part V 8411 Russia and the Newly Independent States 1 Program Services See Part V 4308 South America 3 Program Services See Part V 5242 Central America and the Caribbean Investments 8300000 60 78 8476245 8476245 true false true true false false SCHEDULE F, PART I, LINE 3 PROGRAM SERVICE ACTIVITIES SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE DOES NOT MAINTAIN ONGOING OPERATIONS IN FOREIGN JURISDICTIONS. HOWEVER, THE INSTITUTE'S SCIENTISTS DO TRAVEL TO VARIOUS SCIENTIFIC CONFERENCES IN OTHER COUNTRIES TO SHARE THE INSTITUTE'S SCIENTIFIC DISCOVERIES AND TO LEARN FROM OTHER SCIENTISTS ACROSS THE WORLD. SCHEDULE F, PART I, LINE 3, COLUMN E TYPE OF SERVICE SPECIFIC PROGRAM SERVICE ACTIVITY IN ALL REGIONS IS AGENTS ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS. SCHEDULE F, PART I, LINE 3, COLUMN F ACCOUNTING METHOD THE ACCRUAL METHOD OF ACCOUNTING WAS USED TO DETERMINE THE AMOUNTS IN PART I, LINE 3, COLUMN F. ED GILLENWATERS CONSULTING false BLAIR BLUM PARTNERS CONSULTING false GALA 602005 575005 27000 60882 43062 59163 BRING IT 166160 136160 30000 5656 48873 1500 61107 0 768165 711165 57000 5656 109755 44562 120270 280243 -223243 X X true true X X X X X X true true false false false false false true false PERRY NISEN MD PHD CEO 773380 0 337503 0 4250 0 97917 0 24262 0 1237312 0 0 0 GARY CHESSUM CFO 362441 0 54001 0 2468 0 12000 0 24262 0 455172 0 0 0 GARY RAISL ED D FORMER EVP/CAO/CFP/TREASURER 0 0 0 365372 0 0 0 0 0 365372 0 0 0 GARTH POWIS PHD CENTER DIRECTOR 448257 0 50000 0 5721 0 26500 0 15859 0 546337 0 0 0 DANIEL KELLY MD CNTR DIR/SCI DIR AT LK NONA 497773 0 0 0 4250 0 26500 0 24231 0 552754 0 0 0 EDWARD LEWANDOWSKI PROFESSOR 307210 0 208363 0 3008 0 0 0 23914 0 542495 0 0 0 CARL WARE PHD CENTER DIRECTOR, IIDC 359345 0 53449 0 4741 0 26500 0 16116 0 460151 0 0 0 MICHAEL JACKSON PHD DRUG DISCOVERY & DEV, SR VP 374240 0 55698 0 3133 0 26500 0 23955 0 483526 0 0 0 KRISTIINA VUORI MD PHD PRESIDENT 682730 0 202394 0 1558 0 551500 0 14424 0 1452606 0 0 0 FORM 990, SCHEDULE J, PART I, LINE 1A FIRST CLASS TRAVEL FIRST CLASS TRAVEL IS GENERALLY NOT PERMITTED, EXCEPT UNDER VERY LIMITED AND RARE CIRCUMSTANCES AND CONDITIONS, SUCH AS A MEDICAL CONDITION REQUIREMENT AND URGENT CIRCUMSTANCES. THIS WAS NOT TREATED AS TAXABLE COMPENSATION. HEALTH OR SOCIAL CLUB DUES HEALTH OR SOCIAL CLUB DUES ARE NEGOTIATED IN THE HIRING PROCESS FOR CERTAIN EMPLOYEES. THE AMOUNTS WERE TREATED AS TAXABLE COMPENSATION. FORM 990, SCHEDULE J, PART I, LINE 4A DURING THE YEAR THE ORGANIZATION PAID SEVERANCE UNDER A CONFIDENTIAL SEVERANCE AGREEMENT TO ONE INDIVIDUAL. FORM 990, SCHEDULE J, PART I, LINE 4B SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN THE PARTICIPANTS OF THE 457(F) DEFERRED COMPENSATION PLAN ARE KRISTIINA VUORI AND PERRY NISEN. VESTING FOR KRISTIINA VUORI OCCURS THE EARLIEST OF 4/1/2020 & PERRY NISEN THE EARLIEST OF 9/15/19, OR INVOLUNTARY TERMINATION WITHOUT CAUSE, OR PARTICIPANT'S RESIGNATION FOR GOOD CAUSE, OR THE DATE OF TERMINATION OF THE PLAN. DISTRIBUTION IS A ONE-TIME LUMP SUM PAYMENT UPON VESTING OF 100% OF THE VALUE OF THE PARTICIPANT'S INVESTMENT (COMPRISED OF INSTITUTE CONTRIBUTIONS TO THE CORPUS PLUS ANY INVESTMENT GAINS OR LOSSES THEREON). FORM 990, SCHEDULE J, PART I, LINE 7 NON-FIXED PAYMENTS SOME SENIOR EXECUTIVES HAVE EMPLOYMENT AGREEMENTS STIPULATING A BONUS WILL BE PAID TO THEM PROVIDED CERTAIN GOALS OR ACCOMPLISHMENTS ARE ACHIEVED. FORM 990, SCHEDULE J, PART II, COLUMN (C) RETIREMENT AND OTHER DEFERRED COMPENSATION THE AMOUNT REPORTED IN SCHEDULE J, PART II, COLUMN C FOR KRISTIINA VUORI AND PERRY NISEN INCLUDES AN ACCRUAL OF $525,000 AND $79,167 RESPECTIVELY RELATED TO THE 457 (F) PLAN DESCRIBED ABOVE. THESE AMOUNTS ARE NOT VESTED AND ARE SUBJECT TO SUBSTANTIAL RISK OF FORFEITURE. A COUNTY OF SAN DIEGO 956000934 79742YAQ5 2015-11-12 61963256 SEE PART VI false false false A 0 61673870 61963256 0 0 0 289386 0 0 0 0 0 2015 true false true true A false true true true true true 0.01570 0.01570 false false false false A false true false false true false 0 false 0 false false A false SCHEDULE K, PART I, ROW A, COLUMN (F) Refinance 2006 and 2012 bonds with issue dates of 02/01/2006 and 11/15/2012, respectively. SCHEDULE K, PART I, ROW A For the bond issues listed in Part I, the alternative period used for the reporting requirements in this section is the twelve months ended December 31, 2016. GARY RAISL FORMER OFFICER Relocation Loan X 225000 193137 false true true PERRY NISEN OFFICER QUAL. EMPLOYEE RELOC X 1000000 944444 false true true 1137581 FORM 990, PART I, LINE 1 & PART III, LINE 1 ORGANIZATIONS MISSION SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE CONDUCTS WORLD-CLASS, COLLABORATIVE RESEARCH DEDICATED TO FINDING CURES FOR HUMAN DISEASE, IMPROVING THE QUALITY OF LIFE, AND THUS CREATING A LEGACY FOR ITS EMPLOYEES, PARTNERS, DONORS, AND COMMUNITY. FORM 990, PART III, LINE 4 PROGRAM SERVICE ACCOMPLISHMENTS SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (SBP) IS AN INDEPENDENT NONPROFIT MEDICAL RESEARCH ORGANIZATION THAT CONDUCTS WORLD-CLASS, COLLABORATIVE, BIOLOGICAL RESEARCH AND TRANSLATES ITS DISCOVERIES FOR THE BENEFIT OF PATIENTS. SBP FOCUSES ITS RESEARCH ON CANCER, IMMUNITY, NEURODEGENERATION, METABOLIC DISORDERS AND RARE CHILDREN'S DISEASES. CANCER Insights on the addictions of tumors. Maria Diaz-Meco, Ph.D., professor in the Cancer Metabolism and Signaling Networks Program, published a study in Cell Metabolism that illustrates how tumors can re-wire their surroundings to ensure access to the substances that enable their survival and feed their growth. Targeting the mechanisms that feed their addictions, including the p62 protein located in the tissue surrounding tumors, may lead to more efficacious and less toxic therapies. Biomarker may predict early Alzheimers disease. A new study from Erkki Ruoslahti, M.D., Ph.D., distinguished professor in the Tumor Microenvironment and Cancer Immunology Program, was published in Nature Communications. The study identifies a peptide that may lead to the early detection of Alzheimers disease. The peptide recognizes a protein that is elevated in the brain blood vessels of a mouse model of Alzheimers disease as well as human patients. Stopping pancreatic cancer before it starts. A study co-authored by Jorge Moscat, Ph.D., and Maria Diaz-Meco, Ph.D. and published in Cancer Cell, looks at ways to detect and stop precursors of pancreatic cancer-called PanIN1 lesions-before they become cancer. The findings suggest small molecules that inhibit a protein called MDM2, which is involved in pancreatic cancer progression, may be effective at preventing PanIN1 lesions from turning malignant. How SHARPIN promotes cancer progression. Zeev Ronai, Ph.D., led an international research collaboration showing how the SHARPIN protein acts as a master switch that controls several other proteins linked to melanoma. Inhibiting SHARPIN makes certain types of tumor cells more susceptible to death, and could boost the overall effectiveness of certain anti-cancer therapies. The paper was published in JCI. DISORDERS OF METABOLISM Drug reverses type 2 diabetes in mice. Anthony Pinkerton, Ph.D., and Robert Liddington, Ph.D., worked with Nunzio Bottini, M.D., Ph.D., (UCSD) on a new experimental drug that may spell the end of insulin reliance. The promising drug targets an enzyme (LMPTP) that controls insulin receptor signaling, and helps recover insulin responsiveness. The paper was published in Nature Chemical Biology. More optimization and testing are needed before proven safe for human studies. IMMUNITY Engineering drugs turning on immune checkpoints. John Sedy, Ph.D.,and Carl Ware, Ph.D., laboratory successfully developed a prototype biologic that can tone down the immune system for potential use in patients with autoimmune diseases. The research, published in JBC, describes a drug created from the check point regulator known as herpesvirus entry mediator (HVEM). New Zika virus inhibitor identified. Alexey Terskikh, Ph.D., Alex Strongin, Ph.D., published research in Antiviral Research on a protease inhibitor that blocks Zika virus propagation in human cells and in mice. The molecule appears to be more potent than previously identified inhibitors of the virus, advancing efforts toward a drug to treat Zika infections. Research could lead to better vaccines and antivirals Sumit Chanda, Ph.D., led research that identifies a new regulator of the innate immune response-the immediate, natural response to foreign invaders. The research published in Nature Microbiology suggests that modulating the regulator-an immune checkpoint called KHSRP-may represent the next generation of antiviral drugs, vaccine adjuvants and immunotherapies. Research to combat biothreat of "Black Death". Francesca Marassi, Ph.D., has developed a way to visualize the protein that makes plague bacteria (Y. pestis) so lethal. Although an old disease, the danger to create and use antibiotic-resistant strains as weapons is a real threat. The research, which was published in the Journal of Biomolecular NMR is advancing our understanding of the infectious process. NEUROSCIENCE AND AGING Bipolar disorder discovery could lead to new therapies An international study led by Evan Snyder, M.D., Ph.D., identified the molecular mechanism behind lithiums effectiveness in treating bipolar disorder. The findings, which were published in PNAS, are the first to explain how the disease is rooted in a physiological difference in the regulation of CRMP2-an intracellular protein that regulates neural networks. A protein called SORLA protects against neurodegeneration. Huaxi Xu, Ph.D., professor in the Degenerative Diseases Program, published research in Nature Communications explaining how a brain protein called SORLA protects against Alzheimers disease. The observations suggest that early-stage Alzheimers could be treated with drugs that increase levels of SORLA, or that enhance its interaction with certain receptors in the brain. Inflammaging-when the immune system runs awry with age. Peter Adams, Ph.D., professor in the Tumor Initiation and Maintenance Program, published a study on "inflammaging", a state of chronic, low-grade inflammation linked to age-related diseases such as rheumatoid arthritis, liver disease, atherosclerosis and cancer. The research, published in Nature, is the first to describe how DNA can leak from the cell nucleus and trigger an inflammatory response that harms normal tissue. Fruit flies journey to space to study zero gravity on the heart Karen Ocorr, Ph.D., launched an experiment sending six boxes of fruit flies to the International Space Station (ISS) to study the impact of weightlessness on the heart. The study may help uncover therapies to prevent or treat heart conditions, both in space and on earth. Scientists take a deeper dive into cellular trash Malene Hansen, Ph.D., led the first-ever comprehensive analysis of autophagy in a living animal (C. elegans) during aging. Increasingly, defective autophagy is being linked to age-related disease such as cancer, neurodegeneration, and heart disease. The research published in eLIFE provides information on potential future interventions to help people live longer, healthier lives. CHILDREN'S HEALTH New clues to treat Alagille syndrome. Duc Dong, Ph.D., published a paper in Nature Communications that identifies the cells and genes necessary to make liver ducts-thin tubes that transport bile from the liver to the gallbladder and small intestine. The research, performed in a zebrafish genetic model, is especially meaningful for patients with Alagille syndrome, many of whom suffer from jaundice, liver disease and require liver transplants. Bioinformatics & Structural Biology Genome study links over 100 genetic positions to metabolite levels. Tao Long, Ph.D., led the largest study yet to examine which genes influence the amount of hundreds of different metabolites-the byproducts of metabolism. The research published in Nature Genetics is a step toward measuring metabolite levels to help diagnose diseases. TRANSLATIONAL MEDICINE Innovations in neuron monitoring. The Prebys Centers Anne Bang, Ph.D., is pairing with Shadi Dayeh, Ph.D., (UCSD) to develop new technology to make high-sensitivity recordings in neuronal networks possible, with the goal of developing a device that could be implanted into the brain. Current technology to monitor a neurons health, activity and response to drugs can only study one cell for a brief period of time, and often destroys the cell. This presents a barrier to use in the clinic as well as to study neurons as they actually function-in networks. Drs. Bang and Dayeh received an NSF grant entitled, "Scalable and Fab Compatible High-Density Nanowire Arrays for High Throughput Drug Screening" to advance this research. NCI Chemical Biology Consortium awards two cancer therapeutics projects to SBP. The National Cancer Institutes Experimental Therapeutics Program (NExT) seeks to advance clinical practice and bring improved therapies to patients with cancer by supporting the most promising new drug discovery and development projects. They have recently identified two promising new projects from faculty labs at SBP. Lutz Tautz, Ph.D., and Nick Cosford, Ph.D., have received an award for drug discovery efforts looking to inhibit SHP2, a target implicated in a number of cancers, most notably leukemias, and HER2-postive and triple-negative breast cancers. Jorge Moscat, Ph.D., and Maria Diaz-Meco, Ph.D., are leading a project that targets the protein PHGDH and was also selected to enter the Consortium portfolio, attracting an award of $1.65MM for the initial phases of drug discovery, which included both high throughput screening, medicinal chemistry and structure-based drug design. The Prebys Center, as a dedicated center for this NCI Consortium, has been tasked to work on both of these projects to prosecute the early stages of drug screening with the initial goal of identifying and validating chemical hits prior to moving into more advanced stages of drug discovery. Translational Programs Outreach. With great pleasure, we announce Thomas "T.C." Chung, Ph.D., has rejoined the Institute to spearhead Translational Programs Outreach at the Prebys Center. Dr. Chung previously managed the Molecular Libraries Probe Production Center at SBP, a NIH Common Fund supported program intended to identify new drug targets, particularly in areas of unmet medical needs and rare diseases. In his new role, Dr. Chung will work with PIs at SBP and collaborating Institutes to help translate new discoveries in the molecular and cellular basis of disease through initiating drug discovery projects, with the overall aim of stimulating therapeutic innovations. In September, DSI and SBP announced the launch of a phase 1 clinical trial of a lead compound for the potential treatment of calcification diseases. The ascending dose study in health volunteers is nearly complete, and the compound shows excellent human pharmacokinetics and has been well tolerated thus far. Also the NAMPT project, which originated in the laboratory of Steve Gardell, Ph.D. and was executed in collaboration with the Prebys Center, has delivered a series of proprietary molecules with potential for the treatment of heart failure and muscle degeneration. with the Prebys Center, has delivered a series of proprietary molecules with potential for the treatment of heart failure and muscle degeneration. FORM 990, PART VI, LINE 11B PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990 THE 990 IS PREPARED BY THE FINANCE DEPARTMENT. IT IS REVIEWED BY THE INSTITUTE'S TAX ADVISORS, SELECTED MEMBERS OF MANAGEMENT INCLUDING THE CFO AND AUDIT COMMITTEE AND PROVIDED TO MEMBERS OF THE BOARD PRIOR TO FILING. FORM 990, PART VI, LINE 12C DESCR OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICT OF INTEREST CONFLICT OF INTEREST STATEMENTS ARE GIVEN TO MANAGEMENT STAFF AND PRINCIPAL INVESTIGATORS ON A PERIODIC BASIS TO REPORT ON CONFLICTS OR LACK OF CONFLICTS. THE STATEMENTS ARE REVIEWED ANNUALLY BY THE SENIOR DIRECTOR, INTELLECTUAL PROPERTY AND THE SENIOR DIRECTOR, SPONSORED RESEARCH, WITH A SUMMARY OF THE REVIEW PROVIDED TO THE CFO. AN ASSESSMENT IS MADE AS TO WHETHER A CONFLICT CAN BE MANAGED BY THE EXISTING DEPARTMENTS AND PRACTICES. CONFLICTS ARE BROUGHT TO THE BOARD OF TRUSTEES ON AN AS NEEDED BASIS. CONFLICTS AND POTENTIAL CONFLICTS THAT INVOLVE THE CEO OR THE PRESIDENT ARE BROUGHT TO THE BOARD OF TRUSTEES TO ADDRESS ANY ACTUAL OR POTENTIAL POSSIBILITY THAT THE DESIGNATED REVIEWERS (I.E., SENIOR DIRECTOR, INTELLECTUAL PROPERTY AND THE SENIOR DIRECTOR, SPONSORED RESEARCH, AND THE CFO) COULD BE PRESSURED TO MAKE BIASED DECISIONS IN MANAGING CONFLICTS INVOLVING THE CEO OR PRESIDENT. AS TO RESTRICTIONS IMPOSED: THE INSTITUTE WILL EMPLOY THE MECHANISM THAT IS THE BEST FIT WITH THE FACTS AND CIRCUMSTANCES OF ANY IDENTIFIED CONFLICT OF INTEREST. METHODS TO MANAGE POTENTIAL CONFLICTS/ENFORCEMENT MECHANISM: REVIEWING MANAGEMENT IS RESPONSIBLE FOR MANAGING, REDUCING, OR ELIMINATING REAL OR POTENTIAL CONFLICTS OF INTEREST. EXAMPLES OF CONDITIONS OR RESTRICTIONS THAT MIGHT BE IMPOSED TO MANAGE, REDUCE, OR ELIMINATE CONFLICTS OF INTERESTS INCLUDE: -PUBLIC DISCLOSURE OF SIGNIFICANT FINANCIAL INTERESTS -MONITORING OF RESEARCH BY INDEPENDENT REVIEWERS -MODIFICATION OF THE RESEARCH PLAN -DISQUALIFICATION FROM PARTICIPATION IN THE PORTION OF FUNDED RESEARCH THAT COULD BE AFFECTED BY SIGNIFICANT FINANCIAL INTEREST -DIVESTITURE OF SIGNIFICANT FINANCIAL INTERESTS -SEVERANCE OF RELATIONSHIPS THAT CREATE ACTUAL OR POTENTIAL CONFLICTS -REVIEW OF COMMERCIAL SPONSORED RESEARCH AGREEMENTS FOR SCIENTIFIC MERIT BY THE PROGRAM PLANNING COMMITTEE -REMOVAL OF AN AFFECTED PARTY FROM NEGOTIATION WITH A COMPANY WITH WHICH HE/SHE HAS SIGNIFICANT FINANCIAL INTEREST. FORM 990, PART VI, LINE 15A & 15B PROCESS FOR DETERMINING COMPENSATION COMPENSATION FOR THE CEO, THE PRESIDENT, CHIEF FINANCIAL OFFICER, AND OTHER KEY EMPLOYEES IS ESTABLISHED ACCORDING TO INSTITUTE POLICIES WHICH ARE DESIGNED TO MEET THE IRS STANDARD FOR "REBUTTABLE PRESUMPTION OF REASONABLENESS". THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES, CONSISTING OF FOUR INDEPENDENT TRUSTEES, REVIEWS COMPARABILITY DATA PROVIDED BY AN INDEPENDENT EXTERNAL CONSULTANT THAT INCORPORATES AND EVALUATES INSTITUTE DATA AND THAT OF COMPARABLE ORGANIZATIONS AND MARKETS FROM WHICH THE INSTITUTE DRAWS ITS EXECUTIVE TALENT. UTILIZING THIS INFORMATION, THE COMPENSATION COMMITTEE, WHICH TYPICALLY SEEKS TO ESTABLISH COMPENSATION BETWEEN THE 50TH AND THE 75TH PERCENTILE OF THE COMPARABILITY DATA, MAKES A DETERMINATION WHETHER THE PROPOSED COMPENSATION IS REASONABLE. THE COMPENSATION COMMITTEE HAS BEEN DELEGATED AUTHORITY BY THE BOARD OF TRUSTEES TO REVIEW AND APPROVE COMPENSATION OF ALL POSITIONS EXCEPT FOR THE CEO. THE CEOS COMPENSATION PACKAGE IS REVIEWED AND APPROVED INITIALLY BY THE COMPENSATION COMMITTEE AND THEN GOES TO THE EXECUTIVE COMMITTEE FOR FINAL APPROVAL. THE COMPENSATION COMMITTEE CONTEMPORANEOUSLY AND ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION AND RECOMMENDATION TO THE EXECUTIVE COMMITTEE. IF APPROVED BY THE EXECUTIVE COMMITTEE, THE CEO COMPENSATION PACKAGE IS THEN IMPLEMENTED AND SUCH DOCUMENTATION IS KEPT IN THE WRITTEN AND ELECTRONIC RECORDS OF THE BOARD OF TRUSTEES. THE PROCESS WAS LAST COMPLETED ON JUNE 13, 2017 FOR THE FOLLOWING POSITIONS: 1) CEO 2) PRESIDENT 3) CFO 4) SVP HUMAN RESOURCES 5) VP BUSINESS DEVELOPMENT 6) VP PHILANTHROPY 7) SVP DRUG DISCOVERY & DEVELOPMENT 8) CHIEF SCIENTIFIC ADVISOR/PROFESSOR 9) SCIENTIFC DIRECTOR/PROFESSOR 10) CENTER DIRECTOR/PROFESSOR 11) INFECTIOUS & INFLAMMATORY DISEASE CENTER DIRECTOR/PROFESSOR. FORM 990, PART VI, LINE 19 PROCESS FOR MAKING DOCUMENTS AVAILABLE TO THE PUBLIC DOCUMENTS ARE AVAILABLE UPON REQUEST. FL MED DISCOVERY INSTITUTE AT LAKE NONA 10901 N TORREY PINES ROAD LA JOLLA CA 92037 474997825 RESEARCH CA 501(c)(3) 7 SBPMDI true false false false false false false false false false false false false false false false false false false false